Bluejay Diagnostics (NASDAQ:BJDX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Bluejay Diagnostics (NASDAQ:BJDX) from a hold rating to a sell rating in a research report report published on Monday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of Bluejay Diagnostics stock opened at $0.85 on Monday. The business has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.91. Bluejay Diagnostics has a one year low of $0.82 and a one year high of $16.68. The firm has a market capitalization of $3.80 million, a price-to-earnings ratio of -0.12 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insiders Place Their Bets

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt purchased 64,047 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were acquired at an average price of $1.51 per share, with a total value of $96,710.97. Following the transaction, the insider owned 126,993 shares in the company, valued at $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.10% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.